Hepatic veno-occlusive disease after tranexamic acid administration in oatients undergoing allogeneic hematopoietic stem cell transplantation

Takehiko Mori, Yoshinobu Aisa, Takayuki Shimizu, Rie Yamazaki, Ai Mihara, Tomoharu Yajima, Toshifumi Hibi, Yasuo Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Tranexamic acid is one of the widely used antifibrinolytic agents. In spite of its effective inhibitory activity against plasminogen, thromboembolic adverse events caused by tranexamic acid are rare. We encountered three recipients of allogeneic hematopoietic stem cell transplantation (HSCT) who developed hepatic veno-occlusive disease (VOD) shortly after the administration of tranexamic acid. Hepatic VOD was resolved completely in all patients with the discontinuation of the drug, and with supportive measures with or without intravenous tissue plasminogen activator administration. These findings suggest that administration of tranexamic acid could be one of the possible risk factors for developing hepatic VOD in HSCT recipients.

Original languageEnglish
Pages (from-to)838-839
Number of pages2
JournalAmerican journal of hematology
Volume82
Issue number9
DOIs
Publication statusPublished - 2007 Sep 1

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Hepatic veno-occlusive disease after tranexamic acid administration in oatients undergoing allogeneic hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this